Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205

BACKGROUND: Combined inhibition of platelet-derived growth factor receptor beta signalling and vascular endothelial growth factor promotes vascular normalisation in preclinical models and may lead to increased delivery of chemotherapy to tumour tissue. This phase I/II trial assessed the safety and e...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Hoehler, T, von Wichert, G, Schimanski, C, Kanzler, S, Moehler, M H, Hinke, A, Seufferlein, T, Siebler, J, Hochhaus, A, Arnold, D, Hallek, M, Hofheinz, R, Hacker, U T
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group 2013
Gaiak:
Clinical Study
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3776974/
https://ncbi.nlm.nih.gov/pubmed/23963139
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2013.409
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak